Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Sep 30, 2025 | (FY)Jun 30, 2025 | (Q4)Jun 30, 2025 | (Q3)Mar 31, 2025 | (Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 226.92%85M | 9.03%978M | 7.39%189M | 8.72%511M | -17.92%252M | 146.43%26M | 15.44%897M | 64.49%176M | -7.66%470M | 59.90%307M |
| Net income from continuing operations | 0.67%150M | 70.98%648M | 28.36%86M | 67.19%107M | 61.05%306M | 156.90%149M | 66.23%379M | 644.44%67M | 8.47%64M | 102.13%190M |
| Operating gains losses | -33.33%2M | 150.00%15M | 300.00%4M | --0 | 14.29%8M | 175.00%3M | -95.28%6M | -98.89%1M | -75.00%2M | -74.07%7M |
| Depreciation and amortization | 4.46%117M | 4.32%459M | 4.35%120M | 0.00%114M | 182.50%113M | -34.50%112M | 6.02%440M | 195.04%115M | -37.70%114M | -77.01%40M |
| Asset impairment expenditure | --5M | -72.73%12M | -50.00%10M | --2M | --0 | --0 | 2,100.00%44M | 900.00%20M | --0 | --3M |
| Unrealized gains and losses of investment securities | ---- | ---- | ---- | ---- | ---- | -143.48%-10M | ---- | ---- | ---- | ---- |
| Deferred tax | 20.00%18M | 167.74%83M | --0 | 250.00%3M | 38.30%65M | 15.38%15M | 158.33%31M | -80.00%-27M | -120.00%-2M | 123.81%47M |
| Other non cashItems | 380.00%14M | -124.26%-33M | -78.85%11M | 10.71%31M | -638.46%-70M | -111.63%-5M | 52.81%136M | 642.86%52M | 154.55%28M | -45.83%13M |
| Change In working capital | 10.89%-221M | -48.20%-206M | 19.23%-42M | -3.79%254M | -686.21%-170M | 34.74%-248M | -44.79%-139M | -132.91%-52M | 12.82%264M | 117.79%29M |
| -Change in receivables | 40.77%-77M | -12.94%-96M | 98.78%-1M | 100.00%152M | -338.78%-117M | -1.56%-130M | 53.04%-85M | -249.09%-82M | -33.91%76M | 119.22%49M |
| -Change in inventory | 87.50%-3M | -270.37%-46M | -50.00%3M | -800.00%-18M | -108.97%-7M | 56.36%-24M | 440.00%27M | -90.00%6M | 95.45%-2M | 56.00%78M |
| -Change in payables and accrued expense | -50.00%-141M | 20.99%-64M | -283.33%-44M | -36.84%120M | 53.06%-46M | 52.28%-94M | -201.25%-81M | -44.19%24M | 16.56%190M | -333.33%-98M |
| Cash from discontinued investing activities | -112.82%-5M | 39M | ||||||||
| Operating cash flow | 23.08%80M | 9.03%978M | -40.74%32M | 12.84%668M | -30.39%213M | 218.18%65M | 15.44%897M | -49.53%54M | 16.31%592M | 59.38%306M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 12.93%-101M | 0.98%-406M | -85.96%-212M | -38.00%-138M | 262.16%60M | 27.04%-116M | 3.07%-410M | -770.59%-114M | 2.91%-100M | 82.13%-37M |
| Capital expenditure reported | -8.00%-81M | -14.01%-407M | -41.44%-157M | -1.09%-93M | -173.33%-82M | 39.52%-75M | -2.88%-357M | -3,800.00%-111M | 30.83%-92M | 73.45%-30M |
| Net PPE purchase and sale | ---- | --0 | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Net business purchase and sale | 51.22%-20M | 145.28%24M | -1,400.00%-45M | -462.50%-45M | 2,314.29%155M | -17.14%-41M | 41.76%-53M | -110.34%-3M | 38.46%-8M | 92.71%-7M |
| Net other investing changes | ---- | -192.00%-23M | ---10M | --0 | ---- | ---- | 213.64%25M | ---- | ---- | ---- |
| Cash from discontinued investing activities | 0 | -20M | ||||||||
| Investing cash flow | 25.74%-101M | 0.98%-406M | -2,000.00%-147M | 1.93%-203M | 316.22%80M | 14.47%-136M | 3.07%-410M | -141.18%-7M | -100.97%-207M | 82.13%-37M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -64.22%-179M | -8.49%-524M | 38.51%-99M | 43.54%-83M | -111.82%-233M | -67.69%-109M | 8.00%-483M | -12.59%-161M | -110.00%-147M | 32.52%-110M |
| Net issuance payments of debt | -500.00%-6M | -8.40%-142M | 94.74%-3M | 94.94%-4M | -1,130.77%-134M | 87.50%-1M | -101.54%-131M | -914.29%-57M | -364.71%-79M | 128.26%13M |
| Net common stock issuance | -142.11%-92M | -28.21%-150M | -5.88%-36M | -33.33%-36M | -48.15%-40M | -31.03%-38M | 51.85%-117M | 27.66%-34M | -50.00%-27M | 47.06%-27M |
| Cash dividends paid | -34.29%-47M | -7.56%-185M | 0.00%-57M | -20.00%-36M | 0.00%-57M | -25.00%-35M | 1.15%-172M | 1.72%-57M | -11.11%-30M | 1.72%-57M |
| Net other financing activities | 2.86%-34M | 25.40%-47M | 76.92%-3M | 36.36%-7M | ---2M | ---35M | -46.51%-63M | 71.11%-13M | -37.50%-11M | ---- |
| Cash from discontinued financing activities | 0 | -38M | ||||||||
| Financing cash flow | -21.77%-179M | -8.49%-524M | 63.41%-60M | 15.28%-122M | -77.27%-195M | -126.15%-147M | 8.00%-483M | -14.69%-164M | -105.71%-144M | 32.52%-110M |
| Net cash flow | ||||||||||
| Beginning cash position | 22.60%2.4B | 6.93%1.96B | 11.73%2.17B | 7.08%1.85B | 15.30%1.76B | 6.93%1.96B | 0.60%1.83B | 17.12%1.94B | 29.82%1.72B | 4.87%1.53B |
| Current changes in cash | 8.26%-200M | 828.89%418M | 356.58%195M | 28.45%307M | -16.77%134M | 21.86%-218M | 180.36%45M | -179.17%-76M | -28.87%239M | 190.45%161M |
| Effect of exchange rate changes | -113.89%-5M | 516.67%25M | 640.00%37M | 190.00%18M | -294.12%-66M | 244.00%36M | -20.00%-6M | -16.67%5M | -300.00%-20M | -29.17%34M |
| Cash adjustments other than cash changes | --0 | ---- | ---- | ---- | ---- | ---15M | ---- | ---- | ---- | ---- |
| End cash Position | 24.67%2.2B | 28.37%2.4B | 28.37%2.4B | 11.73%2.17B | 7.08%1.85B | 15.30%1.76B | 6.30%1.87B | 6.30%1.87B | 17.12%1.94B | 29.82%1.72B |
| Free cash from | 90.00%-1M | 5.74%571M | -119.30%-125M | 15.00%575M | -52.54%131M | 94.41%-10M | 25.58%540M | -151.82%-57M | 32.98%500M | 249.37%276M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |